· Published by Health Canada · Official notice
This is duplicated text of a letter from Roche Diagnostics.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 9, 2005
Subject: Important Information on the ACCU-CHEK Aviva Blood Glucose Meter
Dear Health Care Professional,
With this letter, Roche Diagnostics would like to inform you about a technical corrective action relating to the ACCU-CHEK Aviva blood glucose meter. The action described concerns only this system.
Roche maintains close contact with its customers around the world through its sales force representatives and the ACCU-CHEK Customer Care Centers. We have received one single complaint worldwide describing a clearly identifiable, too low and non-plausible blood glucose reading following a measurement performed on the ACCU-CHEK Aviva blood glucose meter. To date, in Canada, we have received no such reports.
The blood glucose meter is equipped with a high performance processor. Studies have shown that in very rare cases a malfunction between the software and the processor can result in an incorrect reading.
Although no cases have occurred in Canada, it cannot be ruled out that individual systems with this malfunction could be in circulation. The only systems that might be affected are those with serial numbers below 526 10 999 999. The serial number is located on the back of the meter (see example).

With regards to these systems, we would like to inform you about methods of quality checking that can be used to identify the malfunction described above:
If the meter powers "on", your patient can continue to use their ACCU-CHEK Aviva blood glucose meter in the usual manner.
If you have any questions on this subject, please contact the ACCU-CHEK Customer Care Center at 1-800-363-7949. Meters showing the type of fault described will be replaced immediately free of charge.
ACTION REQUIRED:
The actions described above are being conducted with the knowledge of Health Canada.
Despite the extremely low probability of the case described above, all necessary steps for a technical correction have been implemented.
Roche Diagnostics, a division of
Hoffmann-La Roche Limited
201 Boul. Armand-Frappier
Laval, Québec H7V 4A2
Canada
Tel.: (450) 686-7050
Fax: (450) 686-7009
Any suspected adverse incident can also be reported to:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675
The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada web site.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Tel.: (613) 954-6522
Fax.: (613) 952-7738
Yours sincerely,
original signed by
Tom Roberts
Vice President, Patient Care
Roche Diagnostics (Canada)
Allan Lane, Ph.D.
Director, Regulatory Affairs and Quality Management
Roche Diagnostics (Canada)